Case Report: Complete metabolic response to alectinib in a TNS1-ALK-rearranged uterine inflammatory myofibroblastic tumor, with stereotactic body radiotherapy for oligoprogression

Inflammatory myofibroblastic tumors of the uterus harboring a TNS1-ALK fusion are rare, and their response to the anaplastic lymphoma kinase ( ALK ) inhibitor alectinib, including the management of oligoprogression with stereotactic body radiotherapy, is poorly documented. Inflammatory myofibroblastic tumors (IMTs) are mesenchymal tumors that, although generally regarded as rare and low-grade neoplasms, have the potential for local recurrence and, rarely, distant metastasis. Anaplastic lymphoma kinase ( ALK ) gene rearrangements are detected in approximately half of IMTs, representing an important biomarker for targeted therapies. Here we present a 53-year-old woman diagnosed with an inflammatory myofibroblastic tumor of uterine origin who developed metastatic recurrence after surgery and, following the detection of ALK fusion positivity ( TNS1-ALK ), achieved a complete metabolic response with alectinib therapy. A CHEK2 mutation was also identified in the patient, who was evaluated for hereditary cancer predisposition. A rapid response was achieved with alectinib in both the pulmonary metastases and the vaginal recurrence site. After approximately 12 months of alectinib therapy, limited (oligoprogressive) disease developed in the lung; stereotactic body radiotherapy was applied to the pulmonary nodules while systemic alectinib therapy was continued. This case highlights the efficacy of ALK inhibitors in the treatment of IMT and the critical importance of identifying molecular targets in rare tumors.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-12
DOI
https://doi.org/10.3389/fphar.2026.2003728
Primary Topic
IgG4-Related and Inflammatory Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Complete metabolic response to alectinib in a TNS1-ALK-rearranged uterine inflammatory myofibroblastic tumor, with stereotactic body radiotherapy for oligoprogression

Ahmet Erkan Bilici, I Bariş, Hakan Özçelik, Burçin Çakan Demirel et al.
Frontiers in Pharmacology
IgG4-Related and Inflammatory Diseases
article

Case Report: Complete metabolic response to alectinib in a TNS1-ALK-rearranged uterine inflammatory myofibroblastic tumor, with stereotactic body radiotherapy for oligoprogression

Ahmet Erkan Bilici, I Bariş, Hakan Özçelik, Burçin Çakan Demirel, Ahmet Levent Güner
article en

Abstract

Inflammatory myofibroblastic tumors of the uterus harboring a TNS1-ALK fusion are rare, and their response to the anaplastic lymphoma kinase ( ALK ) inhibitor alectinib, including the management of oligoprogression with stereotactic body radiotherapy, is poorly documented. Inflammatory myofibroblastic tumors (IMTs) are mesenchymal tumors that, although generally regarded as rare and low-grade neoplasms, have the potential for local recurrence and, rarely, distant metastasis. Anaplastic lymphoma kinase ( ALK ) gene rearrangements are detected in approximately half of IMTs, representing an important biomarker for targeted therapies. Here we present a 53-year-old woman diagnosed with an inflammatory myofibroblastic tumor of uterine origin who developed metastatic recurrence after surgery and, following the detection of ALK fusion positivity ( TNS1-ALK ), achieved a complete metabolic response with alectinib therapy. A CHEK2 mutation was also identified in the patient, who was evaluated for hereditary cancer predisposition. A rapid response was achieved with alectinib in both the pulmonary metastases and the vaginal recurrence site. After approximately 12 months of alectinib therapy, limited (oligoprogressive) disease developed in the lung; stereotactic body radiotherapy was applied to the pulmonary nodules while systemic alectinib therapy was continued. This case highlights the efficacy of ALK inhibitors in the treatment of IMT and the critical importance of identifying molecular targets in rare tumors.

Frontiers in PharmacologyVol. 17
Istanbul Medipol University (TR)
Good health and well-being
IgG4-Related and Inflammatory Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon